NextCure (NXTC) Non-Current Deffered Revenue (2018 - 2022)
NextCure (NXTC) posted quarterly Non-Current Deffered Revenue of $2.5 million for Q3 2022, up 11.43% year-over-year from $2.2 million in Q3 2021, and little changed quarter-over-quarter from $2.5 million in Q2 2022.
NextCure (NXTC) Non-Current Deffered Revenue (2018 - 2022) Analysis & Trends
NextCure's Non-Current Deffered Revenue history runs 5 years deep, the most recent figure standing at $2.5 million for Q3 2022.
- In Q3 2022, Non-Current Deffered Revenue rose 11.43% year-over-year to $2.5 million; the TTM figure through Sep 2022 stood at $2.5 million (up 11.43% YoY), while the FY2021 annual figure was $2.4 million, up 202.02% from the prior year.
- Non-Current Deffered Revenue for Q3 2022 stood at $2.5 million, roughly flat from $2.5 million in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $2.5 million in Q2 2022, with the low at $242000.0 in Q4 2018.
- The 5-year median for Non-Current Deffered Revenue is $784000.0 (2020), against an average of $1.3 million.
- The sharpest annual moves came in 2021 and 2022: Non-Current Deffered Revenue soared 338.46% in 2021, then climbed 7.33% in 2022.
- NextCure's Non-Current Deffered Revenue stood at $242000.0 in 2018, then jumped by 48.35% to $359000.0 in 2019, then surged by 120.61% to $792000.0 in 2020, then soared by 202.02% to $2.4 million in 2021, then gained by 3.55% to $2.5 million in 2022.
- Business Quant data shows NXTC's Non-Current Deffered Revenue at $2.5 million in Q3 2022, $2.5 million in Q2 2022, and $2.4 million in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 147.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | NextCure | 33.72 Mn | 33.72 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 2.48 Mn |
| Jun 30, 2022 | 2.48 Mn |
| Mar 31, 2022 | 2.39 Mn |
| Dec 31, 2021 | 2.39 Mn |
| Sep 30, 2021 | 2.22 Mn |
| Jun 30, 2021 | 2.22 Mn |
| Mar 31, 2021 | 2.22 Mn |
| Dec 31, 2020 | 792,000.00 |
| Sep 30, 2020 | 776,000.00 |
| Jun 30, 2020 | 571,000.00 |
| Mar 31, 2020 | 507,000.00 |
| Dec 31, 2019 | 359,000.00 |
| Sep 30, 2019 | 434,000.00 |
| Jun 30, 2019 | 322,000.00 |
| Mar 31, 2019 | 260,000.00 |
| Dec 31, 2018 | 242,000.00 |